InhibOx goes further than anyone else in value-added virtual screening, and the results bear this out. By adding library sample provision to the service, through MolPort’s highly responsive capability, we offer a unique integrated service..
(PRWEB) December 4, 2009
InhibOx Ltd (Oxford, UK) and MolPort Ltd (Riga, Latvia) announce a strategic partnership to deliver integration in library design and compound provision.
InhibOx, a leader in drug lead identification and library design software and service, uses breakthrough proprietary technology to offer an on-demand virtual screening capability which has demonstrated dramatically improved results over traditional high throughput screening methods. The company has partnered with MolPort, the innovative compound provision consolidator/specialist.
Together, the two companies are able to provide a new, unique service which delivers novel lead candidates in the form of a rich data set and high quality compound samples. Frequently virtual screening identifies compound sets for testing which must be sourced from multiple suppliers, imposing a logistical problem, especially for smaller companies. This integrated service removes these bottlenecks, allowing much improved access to commercially available molecules.
Dr. Paul Finn, CEO of InhibOx, sees this as an important breakthrough in outsourced screening services. “InhibOx goes further than anyone else in value-added virtual screening, and the results bear this out. By adding library sample provision to the service, through MolPort’s highly responsive capability, we offer a unique integrated service which accelerates lead design and lowers the management costs for all customers”.
“Our goal is to make chemical buying as simple as buying a book on Amazon. Screening compound sourcing can be especially complex as it often involves locating suppliers for a large number niche products form companies all around the world. Integrating our database of commercially available compounds with InhibOx virtual screening processes enables streamlining of the road from idea to testable compounds in the clients laboratory. Partnering with InhibOx has allowed us to tailor our services for the needs of computational chemists.” said Dr. Imants Zudans, CEO of MolPort.
InhibOx develops novel and effective computational methods for drug discovery to improve the productivity of lead and candidate identification. The company was founded by Professor W. Graham Richards, former Chairman of Chemistry at the University of Oxford and world leading computational chemist. The company grew from the outstandingly successful Screensaver Lifesaver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox. Since then, InhibOx has built up a significant technology platform in computer-aided drug design. Ongoing activities comprise the development of entirely novel computational drug discovery methods; the development of Scopius, a very large and carefully curated database of commercially-available and virtual chemical structures and their delivery to the life science industries.
MolPort is a rare chemical compound marketplace enabling worry free centralized ordering of chemicals from over 200 companies. To make the marketplace work MolPort has created a world class database of commercially available chemical compounds. The free access online search portal http://www.molport.com features unmatched advanced chemical structure search capabilities that are especially suited for a sophisticated and demanding user.
# # #